{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '10.1.', 'Appendix 1: Regulatory, Ethical, and Study Oversight', 'Considerations', '10.1.1.', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with the following:', '-', 'Consensus ethical principles derived from international guidelines including the', 'Declaration of Helsinki and CIOMS International Ethical Guidelines', '- Applicable ICH-GCP Guidelines', '- Applicable laws and regulations', 'The protocol, protocol amendments, ICF, IB, and other relevant documents (eg,', 'advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and', 'approved by the IRB/IEC before the study is initiated.', 'The IRB/IEC and relevant regulatory authority must be notified of any significant', 'amendment to the protocol, as applicable. Necessary approvals must be given before changes', 'are implemented.', 'The Investigator will be responsible for the following:', '- Providing written summaries of the status of the study to the IRB/IEC annually or', 'more frequently in accordance with the requirements, policies, and procedures', 'established by the IRB/IEC', '- Notifying the IRB/IEC of SAEs or other significant safety findings as required by', 'IRB/IEC procedures', '- Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC,', 'European regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', '10.1.2.', 'Informed Consent Process', 'The Investigator or his/her representative will explain the nature of the study to the patient or', 'his/her legally authorized representative and answer all questions regarding the study.', 'Patients must be informed that their participation is voluntary. Patients or their legally', 'authorized representative will be required to sign a statement of informed consent that meets', 'the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance', 'Portability and Accountability Act requirements, where applicable, and the IRB/IEC or study', 'center.', 'Page 68 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'The medical record must include a statement that written informed consent was obtained', 'before the patient was enrolled in the study and the date the written consent was obtained.', 'The authorized person obtaining the informed consent must also sign the ICF.', 'Patients must be reconsented to the most current version of the ICF(s) during their', 'participation in the study. A copy of the ICF(s) must be provided to the patient.', 'The Investigator must retain the original version of the signed ICF(s). A copy of the signed', 'ICF(s) must be provided to the patient.', 'A patient who is rescreened is not required to sign another ICF unless an updated ICF is', 'available.', '10.1.3.', 'Data Protection', 'Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets', 'that are transferred to the Sponsor will contain the identifier only; patient names or any', 'information which would make the patient identifiable will not be transferred.', 'The patient must be informed that his/her personal study-related data will be used by the', 'Sponsor in accordance with local data protection law. The level of disclosure must also be', 'explained to the patient.', 'The patient must be informed that his/her medical records may be examined by Clinical', 'Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by', 'appropriate IRB/IEC members, and by inspectors from regulatory authorities.', 'Alexion will store anonymized data [ie, data that has been anonymized through removal of', 'elements that will identify the individual directly so that the individual is no longer uniquely', 'identifiable] in the study databases for no less than 15 years after the completion of the study', 'or until the purposes of collection and use are attained, after which data will be destroyed.', 'Health authorities and regulatory authorities may retain and utilize such information for the', \"period set forth in applicable law or as duly determined at the relevant regulatory authority's\", 'discretion.', '10.1.4.', 'Dissemination of Clinical Study Data', 'Study-related information and study results may be posted on the US National Institutes of', 'Health website www.clinicaltrials.gov, the EU website www.clinicaltrialsregister.eu/, or other', 'publicly accessible websites as appropriate and in accordance with local regulations.', '10.1.5.', 'Data Quality Assurance', 'All patient data relating to the study will be recorded on printed or electronic CRF unless', 'transmitted to the Sponsor or designee electronically (eg, laboratory data). The Investigator is', 'responsible for verifying that data entries are accurate and correct by physically or', 'electronically signing the CRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the CRF.', 'Page 69 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}